Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Thyroid Cancer Clinical Trial

Official title:

Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00373711
• Other study ID #: END0003
• Secondary ID: 97454END0003
• Status: Withdrawn
• Start date: May 2007

Study information

• Verified date: April 2011
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Description:

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center

• Treated thyroid cancer.

• Detectable levels of Tg.

• Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.

• Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT

• Patients older than 18-year-old.

• Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.

• Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.

• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.

• Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.

• Pregnant women.

• Healthy volunteers.

• Patients participating in other research studies.

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Drug:
• Iodine-124
2 mCi, oral
• Iodine-123
2 mCi, oral
• F-18 FDG
10-15 mCi, iv

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University